PE20221337A1 - Anticuerpos trem2 y usos de estos - Google Patents

Anticuerpos trem2 y usos de estos

Info

Publication number
PE20221337A1
PE20221337A1 PE2022000821A PE2022000821A PE20221337A1 PE 20221337 A1 PE20221337 A1 PE 20221337A1 PE 2022000821 A PE2022000821 A PE 2022000821A PE 2022000821 A PE2022000821 A PE 2022000821A PE 20221337 A1 PE20221337 A1 PE 20221337A1
Authority
PE
Peru
Prior art keywords
seq
antibody
refers
chain variable
variable region
Prior art date
Application number
PE2022000821A
Other languages
English (en)
Inventor
Forest Hoyt Andrews
Ross Edward Fellows
Ying Tang
Yaming Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20221337A1 publication Critical patent/PE20221337A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN ANTICUERPO QUE SE UNE A TREM2 QUE COMPRENDE UNA REGION VARIABLE DE CADENA LIGERA (LCVR) Y UNA REGION VARIABLE DE CADENA PESADA (HCVR), EN DONDE LCVR COMPRENDE REGIONES DETERMINANTES DE COMPLEMENTARIEDAD (CDR) LCDR1 (SEQ ID NO: 1), LCDR2 (SEQ ID NO: 2) Y LCDR3 (SEQ ID NO: 3), Y LA HCVR COMPRENDE CDR HCDR1 (SEQ ID NO: 4), HCDR2 (SEQ ID NO: 5), Y HCDR3 (SEQ ID NO: 6), TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE DICHO ANTICUERPO.
PE2022000821A 2019-11-22 2020-11-16 Anticuerpos trem2 y usos de estos PE20221337A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939097P 2019-11-22 2019-11-22
PCT/US2020/060663 WO2021101823A1 (en) 2019-11-22 2020-11-16 Trem2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20221337A1 true PE20221337A1 (es) 2022-09-13

Family

ID=73790267

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000821A PE20221337A1 (es) 2019-11-22 2020-11-16 Anticuerpos trem2 y usos de estos

Country Status (17)

Country Link
US (1) US20220281975A1 (es)
EP (1) EP4061842A1 (es)
JP (1) JP7368624B2 (es)
KR (1) KR20220084152A (es)
CN (1) CN114667295B (es)
AU (1) AU2020387380A1 (es)
BR (1) BR112022007944A2 (es)
CA (1) CA3159055A1 (es)
CO (1) CO2022006708A2 (es)
CR (1) CR20220228A (es)
DO (1) DOP2022000104A (es)
EC (1) ECSP22041169A (es)
IL (1) IL293018A (es)
JO (1) JOP20220119A1 (es)
MX (1) MX2022006145A (es)
PE (1) PE20221337A1 (es)
WO (1) WO2021101823A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4066859A1 (en) * 2014-08-08 2022-10-05 Alector LLC Anti-trem2 antibodies and methods of use thereof
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
JP2019531332A (ja) * 2016-07-22 2019-10-31 ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） Ｔｒｅｍ２切断モジュレーター及びその使用
TW202342547A (zh) * 2017-08-03 2023-11-01 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
CN111448212A (zh) * 2017-09-14 2020-07-24 戴纳立制药公司 抗trem2抗体及其使用方法
CA3083660A1 (en) * 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods

Also Published As

Publication number Publication date
CN114667295A (zh) 2022-06-24
WO2021101823A1 (en) 2021-05-27
KR20220084152A (ko) 2022-06-21
CA3159055A1 (en) 2021-05-27
IL293018A (en) 2022-07-01
JP2023502460A (ja) 2023-01-24
JP7368624B2 (ja) 2023-10-24
EP4061842A1 (en) 2022-09-28
CO2022006708A2 (es) 2022-05-31
BR112022007944A2 (pt) 2022-07-12
JOP20220119A1 (ar) 2023-01-30
US20220281975A1 (en) 2022-09-08
CN114667295B (zh) 2024-03-29
MX2022006145A (es) 2022-06-17
DOP2022000104A (es) 2022-07-31
ECSP22041169A (es) 2022-06-30
CR20220228A (es) 2022-06-08
AU2020387380A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
IL277242B1 (en) Antibodies that bind cd39 and uses thereof
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
NZ603607A (en) Cgrp antibodies
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
RS54685B1 (en) ANTI-N3pGlu AMILOID BETA PEPTID ANTIBODIES AND THEIR USES
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
RS53157B (en) SCLEROSTINE ANTIBODIES
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
AR103713A1 (es) Anticuerpos contra tau y sus usos
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
NZ729913A (en) St2l antagonists and methods of use
NZ608660A (en) Anti-cd48 antibodies and uses thereof
AR110719A1 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
HRP20180776T1 (hr) Antagonisti il17c za liječenje upalnih poremećaja